Access selects BioScrip as exclusive distribution and service partner for MuGard

ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has signed an exclusive specialty distribution agreement with BioScrip (Nasdaq: BIOS) for its lead product, MuGard -- an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of radiotherapy and/or chemotherapy.  The agreement aligns the Company with comprehensive access to BioScrip's nationwide distribution platform and the ability to leverage the company's extensive physician relationships, 110 BioScrip specialty pharmacies, mail distribution capability and diversified payor network.  

BioScrip, Inc. ( (Nasdaq: BIOS) is a national provider of specialty pharmacy and home care products and services that partners with patients, physicians, hospitals, healthcare payors and pharmaceutical manufacturers to provide clinical management solutions and delivery of cost-effective access to prescription medications.  Its services are designed to improve clinical outcomes for chronic and acute healthcare conditions while controlling overall healthcare costs.

"As one of the largest, top-tier players in this space, BioScrip is well-established, reputable and focused on tailoring its programs to best fit and meet product manufacturers, provider and payers and patients' pharmacy service needs," said Frank Jacobucci, VP of Sales and Marketing for Access Pharmaceuticals, Inc.  He continued, "In addition to the varied services that they will provide us, this partnership also results in multiple delivery options for patients in need of MuGard, including overnight delivery,  home delivery and live retail pharmacy sites in the top metropolitan areas.  We believe offering various methods of receiving MuGard can significantly increase patient compliance and ultimately provide an important additional weapon to help improve the treatment outcome."

"BioScrip is proud to have been selected by Access to be its exclusive distribution and service partner for MuGard. Our vast clinical, sales and operational specialty pharmacy assets, combined with our deep oncology experience, put us in an unique position to provide services to the patient, manufacturer, provider and payor communities," said Scott Friedman, Senior VP of Trade Relations and Business Development for BioScrip, Inc. "Signing a strong specialty distribution partner is a critical milestone for a successful entrance into the US market," said Jeffrey Davis, CEO of Access Pharmaceuticals, Inc.  He continued, "With its significant resources, deep capabilities and strong commitment to cancer patients, BioScrip is an ideal partner to have in place as we continue executing on our global-commercialization strategy for MuGard."


Access Pharmaceuticals, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Using AI during colonoscopy increases polyp detection rates, reduces costs